<code id='4AFBD770D7'></code><style id='4AFBD770D7'></style>
    • <acronym id='4AFBD770D7'></acronym>
      <center id='4AFBD770D7'><center id='4AFBD770D7'><tfoot id='4AFBD770D7'></tfoot></center><abbr id='4AFBD770D7'><dir id='4AFBD770D7'><tfoot id='4AFBD770D7'></tfoot><noframes id='4AFBD770D7'>

    • <optgroup id='4AFBD770D7'><strike id='4AFBD770D7'><sup id='4AFBD770D7'></sup></strike><code id='4AFBD770D7'></code></optgroup>
        1. <b id='4AFBD770D7'><label id='4AFBD770D7'><select id='4AFBD770D7'><dt id='4AFBD770D7'><span id='4AFBD770D7'></span></dt></select></label></b><u id='4AFBD770D7'></u>
          <i id='4AFBD770D7'><strike id='4AFBD770D7'><tt id='4AFBD770D7'><pre id='4AFBD770D7'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:67853

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In